Why in-use stability matters for opened products:

Once a vial, syringe, pen, or container is opened, its exposure to air, moisture, light, or microbial contaminants increases. The original shelf life no longer applies, and a new “in-use” period must be scientifically determined to guide patients and healthcare professionals. Without data to support in-use conditions, labels may either lack usage instructions or contain unsupported claims—posing risk to product quality and patient safety.

Where labeling gaps become a compliance issue:

Products lacking clear in-use instructions can lead to misuse, contamination, or compromised dosing accuracy. For example, multi-dose injectables without opened vial claims might be stored beyond safe durations. This results in adverse events, patient complaints, or regulatory citations. Stability protocols must therefore simulate post-opening conditions and generate reliable data for labeling decisions.

Regulatory and Technical Context:

ICH, WHO, and regional expectations on in-use stability:

ICH Q1A(R2) and WHO TRS 1010 both emphasize the need for in-use stability studies to justify label claims for reconstituted, diluted, or opened containers. EMA and US FDA guidelines require that such claims be supported by actual data demonstrating stability after first opening, including chemical, microbiological, and physical parameters. CTD Module 3.2.P.8.1 and 3.2.P.8.3 must present this data clearly with proposed label text and justification.

Audit and submission considerations:

Inspectors review whether the label’s “Use within X hours after opening” or “Store at 2–8°C after first use” statements are backed by validated stability results. If claims are missing or unverified, authorities may demand post-approval commitments or issue observations. In-use studies also help determine the appropriateness of device components (e.g., stoppers, connectors, infusion bags) during repeated use or re-access.

Best Practices and Implementation:

Design specific in-use protocols within stability programs:

Simulate real-world usage by opening, sampling, or reconstituting containers under typical pharmacy or clinical conditions. Store opened samples at recommended temperatures (e.g., 2–8°C or room temp) and test them at intervals relevant to intended use—such as 4, 12, 24, or 48 hours post-opening. Evaluate parameters including:

• Assay and degradation
• pH and particulate matter
• Appearance and color
• Microbial limits or sterility (if applicable)

Document container closure re-entry conditions, sampling technique, and sterility precautions.

Define acceptance criteria and translate results to labeling:

Ensure that acceptance ranges match pharmacopeial limits and original product specifications. Where multiple time points are tested, choose the most conservative for labeling (e.g., if 48-hour data shows borderline degradation, label for 24-hour use). Clearly define in-use duration and storage condition in the product label, package insert, and Summary of Product Characteristics (SmPC).

Document results for regulatory filing and inspection defense:

Summarize in-use data in CTD Module 3.2.P.8.3 with supporting graphs, tabulated results, and protocol reference. If in-use stability is a post-approval requirement, track testing status and ensure alignment with variation timelines. Maintain in-use data as part of Annual Product Quality Review (PQR) and reference it in change control documentation when modifying container-closure systems or device accessories.

In-use stability is more than a box to check—it reflects a commitment to safety, usability, and regulatory rigor.